VU2957（瓦利格鲁拉克）的发现：一种代谢型谷氨酸受体正向变构调节剂，作为治疗帕金森病的临床前候选药物进行评估。
Discovery of VU2957 (Valiglurax): An mGlu Positive Allosteric Modulator Evaluated as a Preclinical Candidate for the Treatment of Parkinson's Disease.
作者信息
Panarese Joseph D, Engers Darren W, Wu Yong-Jin, Bronson Joanne J, Macor John E, Chun Aspen, Rodriguez Alice L, Felts Andrew S, Engers Julie L, Loch Matthew T, Emmitte Kyle A, Castelhano Arlindo L, Kates Michael J, Nader Michael A, Jones Carrie K, Blobaum Anna L, Conn P Jeffrey, Niswender Colleen M, Hopkins Corey R, Lindsley Craig W
机构信息
Department of Pharmacology, Vanderbilt University, Nashville, Tennessee 37232, United States.
Vanderbilt Center for Neuroscience Drug Discovery, Vanderbilt University, Nashville, Tennessee 37232, United States.
出版信息
ACS Med Chem Lett. 2018 Oct 16;10(3):255-260. doi: 10.1021/acsmedchemlett.8b00426. eCollection 2019 Mar 14.
Abstract
Herein, we report the discovery of a novel potent, selective, CNS penetrant, and orally bioavailable mGlu PAM, VU0652957 (VU2957, Valiglurax). VU2957 possessed attractive and pharmacological and DMPK properties across species. To advance toward the clinic, a spray-dried dispersion (SDD) formulation of VU2957 was developed to support IND-enabling toxicology studies. Based on its overall profile, VU2957 was evaluated as a preclinical development candidate for the treatment of Parkinson's disease.
摘要
在此，我们报告了一种新型强效、选择性、可穿透中枢神经系统且口服生物利用度高的代谢型谷氨酸受体（mGlu）正变构调节剂VU0652957（VU2957，Valiglurax）的发现。VU2957在不同物种中具有吸引人的药理和药物代谢动力学性质。为推进至临床阶段，开发了VU2957的喷雾干燥分散体（SDD）制剂，以支持开展IND启用毒理学研究。基于其整体特性，VU2957被评估为治疗帕金森病的临床前开发候选药物。
相似文献
1
Discovery of VU2957 (Valiglurax): An mGlu Positive Allosteric Modulator Evaluated as a Preclinical Candidate for the Treatment of Parkinson's Disease.VU2957（瓦利格鲁拉克）的发现：一种代谢型谷氨酸受体正向变构调节剂，作为治疗帕金森病的临床前候选药物进行评估。
ACS Med Chem Lett. 2018 Oct 16;10(3):255-260. doi: 10.1021/acsmedchemlett.8b00426. eCollection 2019 Mar 14.
2
The discovery of VU0652957 (VU2957, Valiglurax): SAR and DMPK challenges en route to an mGlu PAM development candidate.VU0652957（VU2957，Valiglurax）的发现：在开发 mGlu PAM 开发候选药物过程中的 SAR 和 DMPK 挑战。
Bioorg Med Chem Lett. 2019 Jan 15;29(2):342-346. doi: 10.1016/j.bmcl.2018.10.050. Epub 2018 Nov 1.
3
Discovery of VU0467485/AZ13713945: An M PAM Evaluated as a Preclinical Candidate for the Treatment of Schizophrenia.VU0467485/AZ13713945的发现：一种被评估为治疗精神分裂症临床前候选药物的代谢型谷氨酸受体正向变构调节剂
ACS Med Chem Lett. 2016 Dec 16;8(2):233-238. doi: 10.1021/acsmedchemlett.6b00461. eCollection 2017 Feb 9.
6
Discovery of VU6016235: A Highly Selective, Orally Bioavailable, and Structurally Distinct Tricyclic M Muscarinic Acetylcholine Receptor Positive Allosteric Modulator (PAM).VU6016235的发现：一种高选择性、口服生物可利用且结构独特的三环M型毒蕈碱乙酰胆碱受体正变构调节剂（PAM）。
ACS Chem Neurosci. 2024 Sep 24;15(20):3744-54. doi: 10.1021/acschemneuro.4c00465.
7
Synergy between L-DOPA and a novel positive allosteric modulator of metabotropic glutamate receptor 4: implications for Parkinson's disease treatment and dyskinesia.L-DOPA 与代谢型谷氨酸受体 4 的新型正变构调节剂的协同作用：对帕金森病治疗和运动障碍的影响。
Neuropharmacology. 2013 Mar;66:158-69. doi: 10.1016/j.neuropharm.2012.03.022. Epub 2012 Apr 3.
8
mGlu allosteric modulation for treating Parkinson's disease.代谢型谷氨酸受体变构调节剂治疗帕金森病。
Neuropharmacology. 2018 Jun;135:308-315. doi: 10.1016/j.neuropharm.2018.03.027. Epub 2018 Mar 23.
9
Discovery, Structure-Activity Relationship, and Biological Characterization of a Novel Series of 6-((1 H-Pyrazolo[4,3- b]pyridin-3-yl)amino)-benzo[ d]isothiazole-3-carboxamides as Positive Allosteric Modulators of the Metabotropic Glutamate Receptor 4 (mGlu).新型 6-((1 H-吡唑并[4,3- b]吡啶-3-基)氨基)苯并[ d]异噻唑-3-甲酰胺类代谢型谷氨酸受体 4(mGlu4)正变构调节剂的发现、构效关系及生物学特性研究。
J Med Chem. 2019 Jan 10;62(1):342-358. doi: 10.1021/acs.jmedchem.8b00994. Epub 2018 Oct 10.
引用本文的文献
1
Potentiation of group III metabotropic glutamate receptors positively affects neurophysiological features in a mouse model of Rett syndrome.III 型代谢型谷氨酸受体的增强对雷特综合征小鼠模型的神经生理特征产生积极影响。
J Pharmacol Exp Ther. 2025 Jun;392(6):103602. doi: 10.1016/j.jpet.2025.103602. Epub 2025 May 8.
2
Update on mGlu4 modulator patents: 2017 to present.代谢型谷氨酸受体4（mGlu4）调节剂专利更新：2017年至今。
Expert Opin Ther Pat. 2025 May;35(5):463-475. doi: 10.1080/13543776.2025.2467679. Epub 2025 Feb 22.
3
Photoswitchable positive allosteric modulators of metabotropic glutamate receptor 4 to improve selectivity.用于提高选择性的代谢型谷氨酸受体4的光开关型正变构调节剂。
iScience. 2024 May 28;27(6):110123. doi: 10.1016/j.isci.2024.110123. eCollection 2024 Jun 21.
4
Advances and Insights in Positron Emission Tomography Tracers for Metabotropic Glutamate Receptor 4 Imaging.正电子发射断层扫描示踪剂在代谢型谷氨酸受体 4 成像中的研究进展与展望。
J Med Chem. 2024 Jul 11;67(13):10517-10529. doi: 10.1021/acs.jmedchem.3c02431. Epub 2024 Jun 26.
5
The Lateral Metalation of Isoxazolo[3,4-]pyridazinones towards Hit-to-Lead Development of Selective Positive Modulators of Metabotropic Glutamate Receptors.异恶唑并[3,4-d]哒嗪酮的侧向金属化反应：向着代谢型谷氨酸受体选择性正向变构调节剂的成药性研究。
Molecules. 2023 Sep 25;28(19):6800. doi: 10.3390/molecules28196800.
6
binding affinity prediction for metabotropic glutamate receptors using both endpoint free energy methods and a machine learning-based scoring function.使用终点自由能方法和基于机器学习的评分函数预测代谢型谷氨酸受体的结合亲和力。
Phys Chem Chem Phys. 2022 Aug 3;24(30):18291-18305. doi: 10.1039/d2cp01727j.
7
Discovery of VU6028418: A Highly Selective and Orally Bioavailable M Muscarinic Acetylcholine Receptor Antagonist.VU6028418的发现：一种高选择性且口服生物可利用的M型毒蕈碱乙酰胆碱受体拮抗剂。
ACS Med Chem Lett. 2021 Aug 2;12(8):1342-1349. doi: 10.1021/acsmedchemlett.1c00363. eCollection 2021 Aug 12.
8
Roles of Glutamate Receptors in Parkinson's Disease.谷氨酸受体在帕金森病中的作用。
Int J Mol Sci. 2019 Sep 6;20(18):4391. doi: 10.3390/ijms20184391.
9
Discovery of an Orally Bioavailable and Central Nervous System (CNS) Penetrant mGlu Negative Allosteric Modulator (NAM) in Vivo Tool Compound: N-(2-(1 H-1,2,4-triazol-1-yl)-5-(trifluoromethoxy)phenyl)-4-(cyclopropylmethoxy)-3-methoxybenzamide (VU6012962).发现一种具有口服生物利用度和中枢神经系统（CNS）穿透性的 mGlu 负变构调节剂（NAM）体内工具化合物：N-(2-(1H-1,2,4-三唑-1-基)-5-(三氟甲氧基)苯基)-4-(环丙基甲氧基)-3-甲氧基苯甲酰胺（VU6012962）。
J Med Chem. 2019 Feb 14;62(3):1690-1695. doi: 10.1021/acs.jmedchem.8b01810. Epub 2019 Jan 17.
本文引用的文献
1
Discovery, Structure-Activity Relationship, and Biological Characterization of a Novel Series of 6-((1 H-Pyrazolo[4,3- b]pyridin-3-yl)amino)-benzo[ d]isothiazole-3-carboxamides as Positive Allosteric Modulators of the Metabotropic Glutamate Receptor 4 (mGlu).新型 6-((1 H-吡唑并[4,3- b]吡啶-3-基)氨基)苯并[ d]异噻唑-3-甲酰胺类代谢型谷氨酸受体 4(mGlu4)正变构调节剂的发现、构效关系及生物学特性研究。
J Med Chem. 2019 Jan 10;62(1):342-358. doi: 10.1021/acs.jmedchem.8b00994. Epub 2018 Oct 10.
2
Recruitment and Retention in Clinical Trials of Deep Brain Stimulation in Early-Stage Parkinson's Disease: Past Experiences and Future Considerations.早期帕金森病深部脑刺激临床试验中的招募和保留：过去的经验和未来的考虑。
J Parkinsons Dis. 2018;8(3):421-428. doi: 10.3233/JPD-181381.
3
Effects of deep brain stimulation on rest tremor progression in early stage Parkinson disease.深部脑刺激对早期帕金森病静止性震颤进展的影响。
Neurology. 2018 Jul 31;91(5):e463-e471. doi: 10.1212/WNL.0000000000005903. Epub 2018 Jun 29.
4
Discovery and characterization of N-(1,3-dialkyl-1H-indazol-6-yl)-1H-pyrazolo[4,3-b]pyridin-3-amine scaffold as mGlu positive allosteric modulators that mitigate CYP1A2 induction liability.发现并表征N-(1,3-二烷基-1H-吲唑-6-基)-1H-吡唑并[4,3-b]吡啶-3-胺骨架作为可减轻CYP1A2诱导风险的代谢型谷氨酸受体正向变构调节剂。
Bioorg Med Chem Lett. 2018 Aug 15;28(15):2641-2646. doi: 10.1016/j.bmcl.2018.06.034. Epub 2018 Jun 19.
5
2-Position-Selective C-H Perfluoroalkylation of Quinoline Derivatives.喹啉衍生物的 2-位选择性 C-H 全氟烷基化反应。
Org Lett. 2018 Mar 16;20(6):1593-1596. doi: 10.1021/acs.orglett.8b00339. Epub 2018 Mar 8.
6
Increased Potency and Selectivity for Group III Metabotropic Glutamate Receptor Agonists Binding at Dual sites.在结合双位点的 III 组代谢型谷氨酸受体激动剂方面，效力和选择性增强。
J Med Chem. 2018 Mar 8;61(5):1969-1989. doi: 10.1021/acs.jmedchem.7b01438. Epub 2018 Feb 14.
7
Discovery, Structure-Activity Relationship, and Antiparkinsonian Effect of a Potent and Brain-Penetrant Chemical Series of Positive Allosteric Modulators of Metabotropic Glutamate Receptor 4.代谢型谷氨酸受体4强效脑渗透性正变构调节剂化学系列的发现、构效关系及抗帕金森病作用
J Med Chem. 2017 Oct 26;60(20):8515-8537. doi: 10.1021/acs.jmedchem.7b00991. Epub 2017 Oct 12.
8
Epidemiology of Parkinson's disease.帕金森病的流行病学
J Neural Transm (Vienna). 2017 Aug;124(8):901-905. doi: 10.1007/s00702-017-1686-y. Epub 2017 Feb 1.
9
Development and Antiparkinsonian Activity of VU0418506, a Selective Positive Allosteric Modulator of Metabotropic Glutamate Receptor 4 Homomers without Activity at mGlu2/4 Heteromers.代谢型谷氨酸受体4同聚体的选择性正变构调节剂VU0418506的研发及其抗帕金森病活性：VU0418506对代谢型谷氨酸受体2/4异聚体无活性
ACS Chem Neurosci. 2016 Sep 21;7(9):1201-11. doi: 10.1021/acschemneuro.6b00036. Epub 2016 Aug 5.
10
Discovery, Synthesis, and Preclinical Characterization of N-(3-Chloro-4-fluorophenyl)-1H-pyrazolo[4,3-b]pyridin-3-amine (VU0418506), a Novel Positive Allosteric Modulator of the Metabotropic Glutamate Receptor 4 (mGlu4).代谢型谷氨酸受体4（mGlu4）新型正变构调节剂N-（3-氯-4-氟苯基）-1H-吡唑并[4,3-b]吡啶-3-胺（VU0418506）的发现、合成及临床前特性研究
ACS Chem Neurosci. 2016 Sep 21;7(9):1192-200. doi: 10.1021/acschemneuro.6b00035. Epub 2016 May 3.
Zotero 插件